RESUMEN
The development of novel monobactam inhibitors of HCMV protease incorporating a carbon side chain at C-4 and a urea function at N-1 is described. Substitution with small groups at the C-3 position of the beta-lactam ring gave an increase in enzymatic activity and in stability; however, a lack of selectivity against other serine proteases was noted. The use of both tri- and tetrasubstituted urea functionalities gave effective inhibitors of HCMV protease. Benzyl substitution of the urea moiety was beneficial, especially when strong electron-withdrawing groups where attached at the para position. Modest antiviral activity was found in a plaque reduction assay.
Asunto(s)
Antivirales , Citomegalovirus/efectos de los fármacos , Serina Endopeptidasas/metabolismo , Inhibidores de Serina Proteinasa , Urea , beta-Lactamas , Animales , Antivirales/síntesis química , Antivirales/química , Antivirales/farmacología , Bovinos , Línea Celular Transformada , Citomegalovirus/enzimología , Citomegalovirus/fisiología , Humanos , Inhibidores de Serina Proteinasa/síntesis química , Inhibidores de Serina Proteinasa/química , Inhibidores de Serina Proteinasa/farmacología , Relación Estructura-Actividad , Porcinos , Urea/análogos & derivados , Urea/síntesis química , Urea/química , Urea/farmacología , beta-Lactamas/síntesis química , beta-Lactamas/química , beta-Lactamas/farmacologíaRESUMEN
A series of HIV protease inhibitors containing a novel (hydroxyethyl)amidosuccinoyl core has been synthesized. These peptidomimetic structures inhibit viral protease activity at low nanomolar concentrations (IC50 < 10 nM for HIV-1 protease). The inhibition constant (Ki) for inhibitor 19 was determined to be 7.5 pM against HIV-1 and 1.2 nM against HIV-2 proteases, respectively. Several compounds (19-24) inhibited HIV-1 replication in cell culture assays with 50% effective concentrations (EC50) = 3.7-35 nM. This series of inhibitors was found to exhibit poor bioavailability (< 10%) in the rat, following oral administration. The synthesis and biological properties of these compounds are discussed. In addition, an X-ray structure of one of these inhibitors (23) in complex with HIV-2 protease provides insight into the binding mode of this novel class of HIV protease inhibitors.
Asunto(s)
Ácido Aspártico Endopeptidasas/metabolismo , Carbamatos/síntesis química , Inhibidores de la Proteasa del VIH/síntesis química , Proteasa del VIH/metabolismo , VIH-1/fisiología , Valina/análogos & derivados , Replicación Viral/efectos de los fármacos , Administración Oral , Animales , Ácido Aspártico Endopeptidasas/química , Disponibilidad Biológica , Carbamatos/farmacocinética , Carbamatos/farmacología , Cristalografía por Rayos X , Proteína p24 del Núcleo del VIH/biosíntesis , Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/farmacocinética , Inhibidores de la Proteasa del VIH/farmacología , VIH-1/efectos de los fármacos , VIH-1/enzimología , VIH-2/enzimología , Cinética , Modelos Moleculares , Conformación Molecular , Estructura Molecular , Conformación Proteica , Ratas , Estereoisomerismo , Relación Estructura-Actividad , Valina/síntesis química , Valina/farmacocinética , Valina/farmacologíaRESUMEN
We have been investigating peptidomimetic inhibitors of herpes simplex virus (HSV) ribonucleotide reductase (RR). These inhibitors bind to the HSV RR large subunit and consequently prevent subunit association and subsequent enzymatic activity. This report introduces a new series of compounds that contain an extra nitrogen (a ureido function) at the inhibitor N-terminus. This nitrogen improves inhibitor binding potency 50-fold over our first published inhibitor series. Evidence supports that this improvement in potency results from a new hydrogen-bonding contact between the inhibitor and the RR large subunit. This report also provides evidence for the bioactive conformation around two important amino acid residues contained in our inhibitors. A tert-butyl group, which contributes 100-fold to inhibitor potency but does not directly bind to the large subunit, favors an extended beta-strand conformation that is prevalent in solution and in the bound state. More significantly, the bioactive conformation around a pyrrolidine-modified asparagine residue, which contributes over 30 000-fold to inhibitor potency, is elucidated through a series of conformationally restricted analogues.
Asunto(s)
Inhibidores Enzimáticos/síntesis química , Oligopéptidos/síntesis química , Ribonucleótido Reductasas/antagonistas & inhibidores , Simplexvirus/enzimología , Urea/análogos & derivados , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Indicadores y Reactivos , Cinética , Sustancias Macromoleculares , Espectroscopía de Resonancia Magnética , Estructura Molecular , Oligopéptidos/química , Oligopéptidos/farmacología , Unión Proteica , Estructura Secundaria de Proteína , Ribonucleótido Reductasas/química , Espectrometría de Masa Bombardeada por Átomos Veloces , Relación Estructura-ActividadRESUMEN
We have been investigating the potential of a new class of antiviral compounds. These peptidomimetic derivatives prevent association of the two subunits of herpes simplex virus (HSV) ribonucleotide reductase (RR), an enzyme necessary for efficient replication of viral DNA. The compounds disclosed in this paper build on our previously published work. Structure-activity studies reveal beneficial modifications that result in improved antiviral potency in cell culture in a murine ocular model of HSV-induced keratitis. These modifications include a stereochemically defined (2,6-dimethylcyclohexyl)amino N-terminus, two ketomethylene amide bond isosteres, and a (1-ethylneopentyl)amino C-terminus. These three modifications led to the preparation of BILD 1351, our most potent antiherpetic agent containing a ureido N-terminus. Incorporation of the C-terminal modification into our inhibitor series based on a (phenylpropionyl)valine N-terminus provided BILD 1357, a significantly more potent antiviral compound than our previously published best compound, BILD 1263.
Asunto(s)
Antivirales/farmacología , Dipéptidos/farmacología , Inhibidores Enzimáticos/farmacología , Oligopéptidos/farmacología , Ribonucleótido Reductasas/antagonistas & inhibidores , Simplexvirus/efectos de los fármacos , Urea/análogos & derivados , Animales , Antivirales/química , Células Cultivadas , Dipéptidos/química , Inhibidores Enzimáticos/química , Queratitis Herpética/tratamiento farmacológico , Espectroscopía de Resonancia Magnética , Ratones , Oligopéptidos/química , Simplexvirus/enzimología , Estereoisomerismo , Relación Estructura-Actividad , Urea/química , Urea/farmacologíaRESUMEN
The development of peptidomimetic inhibitors of the human cytomegalovirus (HCMV) protease showing sub-micromolar potency in an enzymatic assay is described. Selective substitution of the amino acid residues of these inhibitors led to the identification of tripeptide inhibitors showing improvements in inhibitor potency of 27-fold relative to inhibitor 39 based upon the natural tetrapeptide sequence. Small side chains at P1 were well tolerated by this enzyme, a fact consistent with previous observations. The S2 binding pocket of HCMV protease was very permissive, tolerating lipophilic and basic residues. The substitutions tried at P3 indicated that a small increase in inhibitor potency could be realized by the substitution of a tert-leucine residue for valine. Substitutions of the N-terminal capping group did not significantly affect inhibitor potency. Pentafluoroethyl ketones, alpha,alpha-difluoro-beta-keto amides, phosphonates and alpha-keto amides were all effective substitutions for the activated carbonyl component and gave inhibitors which were selective for HCMV protease. A slight increase in potency was observed by lengthening the P1' residue of the alpha-keto amide series of inhibitors. This position also tolerated a variety of groups making this a potential site for future modifications which could modulate the physicochemical properties of these molecules.
Asunto(s)
Antivirales/síntesis química , Citomegalovirus/efectos de los fármacos , Inhibidores de Proteasas/síntesis química , Antivirales/farmacología , Citomegalovirus/enzimología , Humanos , Inhibidores de Proteasas/farmacología , Relación Estructura-ActividadRESUMEN
Alkaline hydrolysis of leukotriene A4 methyl ester to leukotriene A4 was studied in either methanol or acetone. Hydrolysis in acetone yielded larger amounts of leukotriene A4 than similar hydrolysis in methanol. The maximum amount was obtained 60 minutes after the beginning of the hydrolysis. Leukotriene A4, as well as leukotriene B4 methoxy isomers were obtained from hydrolysis of leukotriene A4 methyl ester in methanol. It was found that initial leukotriene A4 methyl ester concentration affected the amount of LTA4 produced during the hydrolysis. The maximum concentration of leukotriene A4 was obtained by hydrolyzing solutions of 0.25 mg/ml leukotriene methyl ester in acetone. Spontaneous degradation of leukotriene A4 occurred when it was diluted with tris buffer. Addition of bovine serum albumin to the tris buffer significantly prolonged the half life of leukotriene A4.
Asunto(s)
Leucotrienos/síntesis química , Cromatografía Líquida de Alta Presión , Estabilidad de Medicamentos , Hidrólisis , Leucotrieno A4RESUMEN
A series of novel monobactam inhibitors of human cytomegalovirus (HCMV) protease has been described that possess a heterocyclic thiomethyl side chain at C-4. Changes to the heterocycle did not significantly change the inhibitory activity of these compounds in an enzymatic assay, although improvements in solubility and cell culture activity were noted. A number of permutations between C-4 substitutions and N-1 derivatives led to the identification of several beta-lactams with antiviral activity in a plaque reduction assay. N-methyl thiotetrazole-containing compounds were found to be the most potent inhibitors in the enzymatic assay.
Asunto(s)
Citomegalovirus/enzimología , beta-Lactamas/síntesis química , Antivirales/síntesis química , Antivirales/farmacología , Citomegalovirus/efectos de los fármacos , Diseño de Fármacos , Humanos , Estructura Molecular , Inhibidores de Serina Proteinasa/síntesis química , Inhibidores de Serina Proteinasa/farmacología , Tetrazoles/síntesis química , Tetrazoles/farmacología , Urea/análogos & derivados , Proteínas Virales/metabolismo , beta-Lactamas/farmacologíaRESUMEN
A series of 8-heteroarylthiomethyldipyridodiazepinone derivatives were prepared and evaluated for their antiviral profile against wild type virus and the important K103N/Y181C mutant as an indicator for broad activity. 2,6-Dimethylpyridine derivative 16 was found to have a good pharmacokinetic profile in spite of poor metabolic stability in rat liver microsomes.